Angelman Syndrome clinical trials at University of California Health

4 in progress, 2 open to eligible people

Showing trials for

  • REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome

    open to eligible people ages 2-50

    The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.

    at UCLA

  • Angelman Syndrome Natural History Study

    open to all eligible people

    The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future clinical trials.

    at UCSD

  • GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).

    at UCSD UCSF

  • Long-term Extension of GTX-102 in Angelman Syndrome

    Sorry, accepting new patients by invitation only

    The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)

    at UCLA UCSD

Our lead scientists for Angelman Syndrome research studies include .

Last updated: